Literature DB >> 26288698

Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors.

W Michael Seganish1, Thierry O Fischmann1, Brad Sherborne1, Julius Matasi1, Brian Lavey1, William T McElroy1, Deen Tulshian1, James Tata1, Christopher Sondey1, Charles G Garlisi1, Kristine Devito1, James Fossetta1, Daniel Lundell1, Xiaoda Niu1.   

Abstract

We report the identification and synthesis of a series of aminopyrimidin-4-one IRAK4 inhibitors. Through high throughput screening, an aminopyrimidine hit was identified and modified via structure enabled design to generate a new, potent, and kinase selective pyrimidin-4-one chemotype. This chemotype is exemplified by compound 16, which has potent IRAK4 inhibition activity (IC50 = 27 nM) and excellent kinase selectivity (>100-fold against 99% of 111 tested kinases), and compound 31, which displays potent IRAK4 activity (IC50 = 93 nM) and good rat bioavailability (F = 42%).

Entities:  

Keywords:  IRAK4; inflammation; kinase inhibitor; structure-based drug design

Year:  2015        PMID: 26288698      PMCID: PMC4538434          DOI: 10.1021/acsmedchemlett.5b00279

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  13 in total

Review 1.  Toll-like receptor signalling.

Authors:  Shizuo Akira; Kiyoshi Takeda
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

2.  Ligand efficiency: a useful metric for lead selection.

Authors:  Andrew L Hopkins; Colin R Groom; Alexander Alex
Journal:  Drug Discov Today       Date:  2004-05-15       Impact factor: 7.851

3.  Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.

Authors:  William T McElroy; W Michael Seganish; R Jason Herr; James Harding; Jinhai Yang; Larry Yet; Venukrishnan Komanduri; Koraboina Chandra Prakash; Brian Lavey; Deen Tulshian; William J Greenlee; Christopher Sondey; Thierry O Fischmann; Xiaoda Niu
Journal:  Bioorg Med Chem Lett       Date:  2015-03-28       Impact factor: 2.823

Review 4.  IRAK-4--a shared NF-kappaB activator in innate and acquired immunity.

Authors:  Nobutaka Suzuki; Takashi Saito
Journal:  Trends Immunol       Date:  2006-12       Impact factor: 16.687

Review 5.  Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.

Authors:  Divya Chaudhary; Shaughnessy Robinson; Donna L Romero
Journal:  J Med Chem       Date:  2014-12-05       Impact factor: 7.446

6.  The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells.

Authors:  Kyung W Song; Francisco X Talamas; Rebecca T Suttmann; Pam S Olson; Jim W Barnett; Simon W Lee; Kelly D Thompson; Sue Jin; Mohammad Hekmat-Nejad; Terrence Z Cai; Anthony M Manning; Ronald J Hill; Brian R Wong
Journal:  Mol Immunol       Date:  2009-01-31       Impact factor: 4.407

7.  Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.

Authors:  L Nathan Tumey; Diane H Boschelli; Niala Bhagirath; Jaechul Shim; Elizabeth A Murphy; Deborah Goodwin; Eric M Bennett; Mengmeng Wang; Lih-Ling Lin; Barry Press; Marina Shen; Richard K Frisbie; Paul Morgan; Shashi Mohan; Julia Shin; Vikram R Rao
Journal:  Bioorg Med Chem Lett       Date:  2014-03-29       Impact factor: 2.823

8.  The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation.

Authors:  Magdalena Koziczak-Holbro; Amanda Littlewood-Evans; Bernadette Pöllinger; Jiri Kovarik; Janet Dawson; Gerhard Zenke; Christoph Burkhart; Matthias Müller; Hermann Gram
Journal:  Arthritis Rheum       Date:  2009-06

9.  Signalling mechanisms for Toll-like receptor-activated neutrophil exocytosis: key roles for interleukin-1-receptor-associated kinase-4 and phosphatidylinositol 3-kinase but not Toll/IL-1 receptor (TIR) domain-containing adaptor inducing IFN-beta (TRIF).

Authors:  Agnieszka A Brzezinska; Jennifer L Johnson; Daniela B Munafo; Beverly A Ellis; Sergio D Catz
Journal:  Immunology       Date:  2008-11-14       Impact factor: 7.397

10.  IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease.

Authors:  Kirk A Staschke; Sucai Dong; Joy Saha; Jingyong Zhao; Nathan A Brooks; Deena L Hepburn; Jinqi Xia; Muhammet F Gulen; Zizhen Kang; Cengiz Z Altuntas; Vincent K Tuohy; Raymond Gilmour; Xiaoxia Li; Songqing Na
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

View more
  9 in total

1.  Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4).

Authors:  Li Wang; Ryan Ferrao; Qiubai Li; John M Hatcher; Hwan Geun Choi; Sara J Buhrlage; Nathanael S Gray; Hao Wu
Journal:  J Biol Chem       Date:  2019-01-24       Impact factor: 5.157

2.  Crystal structure of human IRAK1.

Authors:  Li Wang; Qi Qiao; Ryan Ferrao; Chen Shen; John M Hatcher; Sara J Buhrlage; Nathanael S Gray; Hao Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-05       Impact factor: 11.205

3.  Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors.

Authors:  Gilles Ouvry; Laurence Clary; Loïc Tomas; Michèle Aurelly; Laetitia Bonnary; Emilie Borde; Claire Bouix-Peter; Laurent Chantalat; Claire Defoin-Platel; Sophie Deret; Mathieu Forissier; Craig S Harris; Tatiana Isabet; Laurent Lamy; Anne-Pascale Luzy; Jonathan Pascau; Catherine Soulet; Alessandro Taddei; Nathalie Taquet; Etienne Thoreau; Emeric Varvier; Emmanuel Vial; Laurent F Hennequin
Journal:  ACS Med Chem Lett       Date:  2019-10-04       Impact factor: 4.345

4.  Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors.

Authors:  Yan Chen; Rajinder Singh; Nan Lin; Vanessa Taylor; Esteban S Masuda; Donald G Payan
Journal:  ACS Med Chem Lett       Date:  2022-04-04       Impact factor: 4.632

5.  The Legionella kinase LegK7 exploits the Hippo pathway scaffold protein MOB1A for allostery and substrate phosphorylation.

Authors:  Pei-Chung Lee; Ksenia Beyrakhova; Caishuang Xu; Michal T Boniecki; Mitchell H Lee; Chisom J Onu; Andrey M Grishin; Matthias P Machner; Miroslaw Cygler
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

6.  Graphene Oxide-Based Nanocomposites Decorated with Silver Nanoparticles as an Antibacterial Agent.

Authors:  Sławomir Jaworski; Mateusz Wierzbicki; Ewa Sawosz; Anna Jung; Grzegorz Gielerak; Joanna Biernat; Henryk Jaremek; Witold Łojkowski; Bartosz Woźniak; Jacek Wojnarowicz; Leszek Stobiński; Artur Małolepszy; Marta Mazurkiewicz-Pawlicka; Maciej Łojkowski; Natalia Kurantowicz; André Chwalibog
Journal:  Nanoscale Res Lett       Date:  2018-04-23       Impact factor: 4.703

7.  Design of a Novel and Selective IRAK4 Inhibitor Using Topological Water Network Analysis and Molecular Modeling Approaches.

Authors:  Myeong Hwi Lee; Anand Balupuri; Ye-Rim Jung; Sungwook Choi; Areum Lee; Young Sik Cho; Nam Sook Kang
Journal:  Molecules       Date:  2018-11-29       Impact factor: 4.411

8.  Synthesis and in Vitro Evaluation of Novel 5-Nitroindole Derivatives as c-Myc G-Quadruplex Binders with Anticancer Activity.

Authors:  Vijaykumar D Nimbarte; Julia Wirmer-Bartoschek; Santosh L Gande; Islam Alshamleh; Marcel Seibert; Hamid Reza Nasiri; Frank Schnütgen; Hubert Serve; Harald Schwalbe
Journal:  ChemMedChem       Date:  2021-03-22       Impact factor: 3.466

Review 9.  Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.

Authors:  Jack W Singer; Angela Fleischman; Suliman Al-Fayoumi; John O Mascarenhas; Qiang Yu; Anupriya Agarwal
Journal:  Oncotarget       Date:  2018-09-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.